<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1405-9940</journal-id>
<journal-title><![CDATA[Archivos de cardiología de México]]></journal-title>
<abbrev-journal-title><![CDATA[Arch. Cardiol. Méx.]]></abbrev-journal-title>
<issn>1405-9940</issn>
<publisher>
<publisher-name><![CDATA[Instituto Nacional de Cardiología Ignacio Chávez]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1405-99402015000400278</article-id>
<article-id pub-id-type="doi">10.1016/j.acmx.2014.12.001</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Desarrollo de trastornos de conducción e indicaciones de marcapasos postimplante de válvula aórtica CoreValve ® por vía endovascular. Incidencia y seguimiento en un solo centro]]></article-title>
<article-title xml:lang="en"><![CDATA[New conduction disturbances and pacemaker indications after CoreValve ® transcatheter aortic valve replacement. Incidence and follow up in a single center experience]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Aversa]]></surname>
<given-names><![CDATA[Eliana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Muratore]]></surname>
<given-names><![CDATA[Claudio A.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Nemesio]]></surname>
<given-names><![CDATA[M. Laura]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Tentori]]></surname>
<given-names><![CDATA[Maria Cristina]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Payaslian]]></surname>
<given-names><![CDATA[Miguel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Fernández Servicio de Cardiología ]]></institution>
<addr-line><![CDATA[Buenos Aires ]]></addr-line>
<country>Argentina</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2015</year>
</pub-date>
<volume>85</volume>
<numero>4</numero>
<fpage>278</fpage>
<lpage>283</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S1405-99402015000400278&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S1405-99402015000400278&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S1405-99402015000400278&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen:  Introducción: El implante de válvula aórtica transcatéter (TAVI) surge como alternativa a la cirugía en pacientes con estenosis aórtica grave y elevado riesgo quirúrgico o inoperables. Una de sus complicaciones son los nuevos trastornos de conducción, que en ocasiones requieren la colocación de un marcapasos.  Objetivos: Evaluar la incidencia de nuevos trastornos de conducción e indicaciones de marcapasos en pacientes sometidos a TAVI con CoreValve® (Medtronic Inc., Minneapolis, Minnesota, EE. UU.).  Métodos: Se incluyeron 28 pacientes con edad media de 80 años. Todos los pacientes tenían un ECG previo e inmediatamente posterior al implante y fueron monitorizados durante el mismo. Además se realizó seguimiento con monitorización holter de 24 h al mes, a los 6 meses y al año del implante, y se evaluó la telemetría de los marcapasos implantados.  Resultados: En el ECG preimplante se encontraron: 7 pacientes con bloqueo de rama derecha y 7 con bloqueo de rama izquierda (BRI). En el ECG postimplante inmediato se observaron 7 nuevos casos de BRI, 3 de ellos ocurrieron durante la valvuloplastia y 4 al finalizar el implante. Seis pacientes requirieron marcapasos por bloqueo AV completo (BAVC) paroxístico o permanente. En el seguimiento al año, el BRI postimplante desapareció en 3 de los 5 pacientes, uno de ellos seguía con BRI y un paciente tuvo un BAVC tardío.  Conclusiones: En nuestra serie, los trastornos de conducción son frecuentes después de TAVI. La incidencia de BRI nuevo fue del 25%. El BAVC intra- o post-TAVI inmediato requieren estimulación ventricular permanente. Es importante realizar un seguimiento frecuente en aquellos pacientes con nuevos bloqueos completos de rama izquierda ya que un 3% pueden avanzar a BAVC a mediano plazo.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Summary:  Introduction: Transcatheter aortic valve implantation (TAVI) is currently reserved for patients with symptomatic aortic stenosis and high surgical risk. One major limiting factor related to TAVI procedural complications is conduction abnormalities and the need for permanent pacemaker implantation.  Objectives: Evaluate the incidence of new conduction disturbances and pacemaker indications in patients with TAVI CoreValve® prosthesis (Medtronic Inc. Minneapolis, Minnesota, United States).  Methods: We included 28 patients, mean age 80 years. ECG parameters were evaluated previous and after implantation. All patients were monitorized during TAVI. Follow up Holter monitoring was performed at one, 6 and 12 months after the procedure and we also evaluated telemetry of implanted pacemaker.  Results: In previous ECG we found 7 patients had right bundle branch block and 7 patients had left bundle brunch block (LBBB). The post implant ECG showed 7 new LBBB: 3 during valvuloplasty and 4 on the end of it. Six patients required pacemaker implantation for permanent or paroxysmal complete AV block (CAVB). At one year follow up, 3 patients with LBBB during valvuloplasty had a normal ECG, one still had LBBB and one an asymptomatic CAVB found in Holter monitoring.  Conclusions: Conduction abnormalities are frequent after CoreValve® aortic valve prosthesis implantation. The incidence of new LBBB was 25%. CAVB during or post TAVI require PM implantation. New LBBB may need a closer follow up because in a 3% of the cases it may progress to CAVB.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Estenosis aórtica]]></kwd>
<kwd lng="es"><![CDATA[Válvula aórtica percutánea]]></kwd>
<kwd lng="es"><![CDATA[CoreValve®]]></kwd>
<kwd lng="es"><![CDATA[Nuevos trastornos de conducción]]></kwd>
<kwd lng="es"><![CDATA[Indicaciones de marcapasos]]></kwd>
<kwd lng="en"><![CDATA[Aortic stenosis]]></kwd>
<kwd lng="en"><![CDATA[Transcatheter aortic valve implantation]]></kwd>
<kwd lng="en"><![CDATA[CoreValve®]]></kwd>
<kwd lng="en"><![CDATA[New conduction disturbances]]></kwd>
<kwd lng="en"><![CDATA[Pacemaker indications.]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Spectrum of calcific aortic valve disease pathogenesis, disease progression, and treatment strategies]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Freeman]]></surname>
<given-names><![CDATA[R.V.]]></given-names>
</name>
<name>
<surname><![CDATA[Otto]]></surname>
<given-names><![CDATA[C.M.]]></given-names>
</name>
</person-group>
<source><![CDATA[Circulation]]></source>
<year>2005</year>
<volume>111</volume>
<page-range>3316-26</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Persistent annual permanent pacemaker implantation rate after surgical aortic valve replacement in patients with severe aortic stenosis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Van]]></surname>
<given-names><![CDATA[N.M.]]></given-names>
</name>
<name>
<surname><![CDATA[Head]]></surname>
<given-names><![CDATA[S.J.]]></given-names>
</name>
<name>
<surname><![CDATA[de]]></surname>
<given-names><![CDATA[W.]]></given-names>
</name>
</person-group>
<source><![CDATA[Ann Thorac Surg.]]></source>
<year>2012</year>
<volume>94</volume>
<page-range>1143-9</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Iung]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Baron]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Burchart]]></surname>
<given-names><![CDATA[E.G.]]></given-names>
</name>
</person-group>
<source><![CDATA[Eur Heart J.]]></source>
<year>2003</year>
<volume>24</volume>
<page-range>1231-43</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Long term outcomes after transcatheter aortic valve implantation in high-risk patients with severe aortic stenosis: The U.K. TAVI (United Kingdom Transcatheter Aortic Valve Implantation) Registry]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moat]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
<name>
<surname><![CDATA[Ludman]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Belder]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<source><![CDATA[J Am Coll Cardiol.]]></source>
<year>2011</year>
<volume>58</volume>
<page-range>2130-8</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Influence of gender on clinical outcomes following transcatheter aortic valve implantation from the UK transcatheter aortic valve implantation registry and the National Institute for Cardiovascular Outcomes Research]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Al-Lamee]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Broyd]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Parker]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Cardiol.]]></source>
<year>2014</year>
<volume>113</volume>
<page-range>522-8</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Early and persistent intraventricular conduction abnormalities and requirements for pacemakin following percutaneous replacement of the aortic valve]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Piazza]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
<name>
<surname><![CDATA[Onuma]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
<name>
<surname><![CDATA[Jesserun]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
</person-group>
<source><![CDATA[JACC Cardiovasc Interv.]]></source>
<year>2008</year>
<volume>1</volume>
<page-range>310-6</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Incidence and predictors of left bundle branch block after transcatheter aortic valve implantation]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aktug]]></surname>
<given-names><![CDATA[Ö.]]></given-names>
</name>
<name>
<surname><![CDATA[Dohmen]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Brehmer]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
</person-group>
<source><![CDATA[Int J Cardiol.]]></source>
<year>2012</year>
<volume>160</volume>
<page-range>26-30</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Atrioventricular block after transcatheter balloon expandable aortic valve implantation]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sinhal]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Altwegg]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Pasupati]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<source><![CDATA[JACC Cardiovasc Interv.]]></source>
<year>2008</year>
<volume>1</volume>
<page-range>305-9</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Puesta en marcha del programa de implantación transcatéter de válvula aórtica empleando la válvula expandible por balón Edwards Sapien XT. Informe del primer caso en México]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Eid-Lidt]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Gaspar]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Arias]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<source><![CDATA[Arch Cardiol Mex.]]></source>
<year>2014</year>
<volume>84</volume>
<page-range>133-5</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Incidence and predictors of atrioventricular conduction impairment after transcatheter aortic valve implantation]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Roten]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Wenaweser]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Delacrétaz]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Cardiol.]]></source>
<year>2010</year>
<volume>106</volume>
<page-range>1473-80</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Alteraciones de la conducción auriculoventricular y predictores de la necesidad de marcapasos tras el implante percutáneo de la prótesis aórtica CoreValve®]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Muñoz-García]]></surname>
<given-names><![CDATA[A.J.]]></given-names>
</name>
<name>
<surname><![CDATA[Hernández-García]]></surname>
<given-names><![CDATA[J.M.]]></given-names>
</name>
<name>
<surname><![CDATA[Jiménez-Navarro]]></surname>
<given-names><![CDATA[M.F.]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev Esp Cardiol.]]></source>
<year>2010</year>
<volume>63</volume>
<page-range>1444-51</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Incidence, predictors and outcome of conduction disorders after transcatheter self-expandable aortic valve implantation]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fraccaro]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Buja]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Tarantini]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Cardiol.]]></source>
<year>2011</year>
<volume>107</volume>
<page-range>747-54</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Predictors and course of high-degree atrioventricular block after transcatheter aortic valve implantation using the CoreValve revalving system]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Guetta]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
<name>
<surname><![CDATA[Goldenberg]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Segev]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Cardiol.]]></source>
<year>2011</year>
<volume>108</volume>
<page-range>1600-5</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Permanent pacemaker implantation after isolated aortic valve replacement: Incidence, indications, and predictors]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dawkins]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Hobson]]></surname>
<given-names><![CDATA[A.R.]]></given-names>
</name>
<name>
<surname><![CDATA[Kalra]]></surname>
<given-names><![CDATA[P.R.]]></given-names>
</name>
</person-group>
<source><![CDATA[Ann Thorac Surg.]]></source>
<year>2008</year>
<volume>85</volume>
<page-range>108-12</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Postoperative permanent pacemaker implantation in patients undergoing trans-catheter aortic valve implantation: What is the incidence and are there any predicting factors?]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bates]]></surname>
<given-names><![CDATA[M.G.]]></given-names>
</name>
<name>
<surname><![CDATA[Matthews]]></surname>
<given-names><![CDATA[I.G.]]></given-names>
</name>
<name>
<surname><![CDATA[Fazal]]></surname>
<given-names><![CDATA[I.A.]]></given-names>
</name>
</person-group>
<source><![CDATA[Interact Cardiovasc Thorac Surg.]]></source>
<year>2011</year>
<volume>12</volume>
<page-range>243-53</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
